Drug Profile
PA 1420
Alternative Names: Polymyxin EILatest Information Update: 15 May 2001
Price :
$50
*
At a glance
- Originator Chiron Corporation
- Class Antibacterials; Peptide antibiotics
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
Most Recent Events
- 15 May 2001 Discontinued-Clinical for Cystic fibrosis-associated respiratory tract infections in USA (Inhalation)
- 15 May 2001 Discontinued-Clinical for Pseudomonal infections in USA (Inhalation)
- 05 Oct 2000 PathoGenesis Corporation has been acquired by Chiron Corporation